John Butler, Akebia Therapeutics CEO
March 27, 2024 10:35 PM EDTUpdated 10:40 AM
Pharma
FDA+

Up­dat­ed: FDA ap­proves Ake­bi­a's ane­mia drug af­ter say­ing no in 2022

Kyle LaHucik

Senior Reporter

The FDA on Wednes­day green­lit Ake­bia Ther­a­peu­tics’ treat­ment for ane­mia due to chron­ic kid­ney dis­ease, mark­ing a turn­around for vadadu­s­tat, which …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump names Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, Sur­geon Gen­er­al picks

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

FDA vac­cine chief Pe­ter Marks pledges to stay as long as he's wel­come

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times